Epoprostenol
Generic name
Epoprostenol
Brand name
ATC Code
B01AC09
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Half-life: < 6 minutes
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Pulmonary hypertension, sepsis with severely reduced circulation |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ANTITHROMBOTIC AGENTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Vitamin K antagonists | ||
|---|---|---|
| B01AA07 | ||
| B01AA04 | ||
| Heparin group | ||
|---|---|---|
| B01AB04 | ||
| B01AB09 | ||
| B01AB05 | ||
| B01AB01 | ||
| B01AB06 | ||
| B01AB10 | ||
| Platelet aggregation inhibitors excl. heparin | ||
|---|---|---|
| B01AC06 | ||
| B01AC04 | ||
| Enzymes | ||
|---|---|---|
| B01AD02 | ||
| B01AD01 | ||
| B01AD04 | ||
| Direct thrombin inhibitors | ||
|---|---|---|
| B01AE07 | ||
| Direct factor Xa inhibitors | ||
|---|---|---|
| B01AF02 | ||
| B01AF01 | ||
References
- Doran A, et al, Advances in prostanoid infusion therapy for pulmonary arterial hypertension, J Infus Nurs, 2008, Nov-Dec;31(6), 336-45
- Ivy DD, et al, Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil, Am J Cardiol, 2007, Mar 1;99(5), 696-8
- Rosenzweig EB, et al, Pulmonary arterial hypertension in children, Pediatr Pulmonol, 2004, Jul;38(1), 2-22
- Lammers AE, et al, Epoprostenol treatment in children with severe pulmonary hypertension, Heart, 2007, Jun;93(6), 739-43
- Melnick L, et al, Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension, Am J Cardiol, 2010, May 15;105(10), 1485-9
- Nakayama T, et al, Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children, Circ J, 2007, Nov;71(11), 1785-90
- Farber HW, et al, Practical considerations for therapies targeting the prostacyclin pathway, Eur Respir Rev, 2016, 25, 361–363
- Hansmann G, et al., 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT, J Heart Lung Transpl,, 2019, 38(9), 879-901
- Barnes H, et al., Prostacyclin for pulmonary arterial hypertension , Cochrane Database Syst Rev. 2019 May; 2019(5), 2019, May 1;5(5), CD012785
- Barnes H, et al., Prostacyclin for pulmonary arterial hypertension, Cochrane Database Syst Rev. 2019 May; 2019(5), 2019, May 1;5(5), CD012785
Changes
Therapeutic Drug Monitoring
Overdose
